Post by
prophetoffactz on Dec 29, 2023 9:43pm
2024
Some time ago Gilles noted that a NASDAQ listing could require a stock roll-back and that stocks don't tend to like roll-backs. He said perhaps CZO could simultaneously announce a PGX deal with a NASDAQ uplisting as a counter. This merger comes with a potential 3-4 to 1 roll-back announcement. A PGX deal may have to wait until the merger is completed along with PGX scale-up. We will see if a diagnostic deal is announced soon. The market could also benefit from a clear plan for the merged entity detailing priorities and the path to commercialization. That could come early in the New Year with the company's new name, etc. Regardless of what the stock price does near term the new company has a potential path to realize numerous key events in 2024.
1) A North American growth hormone deficiency diagnostic deal. Novo Nordisk paid ~C$250 million(cash, equity) plus tiered royalties. H.C. Wainwright had a US$15 target price for AEZS likely substantially due to its diagnostic test which could be approved for its key market(children) in 2024 and relicensed for North America.
2) A PGX deal in the $4 billion CoQ10 market according to Gilles. PGX smashed the industry gold standard in the University of Albert trial. At the AGM Gilles said CZO is in talks with serious companies who understand the unique selling point of bioavailability. What could gold standard market share be in a $4 billion market.
3) 100L PGX scale-up and the decision to go commercial in the $1 billion immune booster market. PGX-YBG has been 5X more immune stimulative in human cell-lines and could set a new gold standard for purity. What could gold standard market share be in this $1 billion market in the much larger immune booster market.
4) Avenanthramide safety/tolerability, preliminary efficacy clinical results. CZO says this could be CZO's biggest product. The NSAID market is $50 billion per year.
5) Avenanthramide pill partner expected with successful Phase I/IIa safety/tolerability and potential preliminary efficacy data in patients suffering mild inflammation.
6) Fibrosis clinical trial decision and regulatory filing. Dr. Martin Kolb says PGX-YBG could profoundly change the treatment landscape. Avalyn raised C$80 million going into its Phase I clinical trial.
7) Wound healing data and partner. Dr. Li talked about Intel Inside given the breadth of application. CZO has already past the gold standard model others use. Gilles calls it a "home run". Wound healing claims for cosmeceuticals can also be advanced.
8) AIM Biologicals Phase I clinical trial decision in billion dollar potential market.
9) Launch of beta glucan and avenanthramide powders with Symrise.
10) CZO's major client initiates reordering.
11) Malted avenanthramide for the neutraceutical market. They can now produce from one plant what four could produce with the same input. Claims could be strengthened with the success of the avenanthramide clinical trial.
12) Tax loss carryforwards of C$113.4 million as the decision to go commercial with PGX are made; including with potential serious partners.
13) Potential biotech bull market as interest rates are cut.